Anatomic fat depots and coronary plaque among human immunodeficiency virus-infected and uninfected men in the Multicenter AIDS Cohort Study

Open Forum Infectious Diseases

Volumn 3, Issue 2, 2016, Pages

  Palella, Frank J ^a   McKibben, Rebeccah ^b   Post, Wendy S ^b   Li, Xiuhong ^b   Budoff, Matthew ^c   Kingsley, Lawrence ^d   Witt, Mallory D ^c   Jacobson, Lisa P ^b   Brown, Todd T ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Adiposity; Coronary plaque

Indexed keywords

ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCORING SYSTEM;

EID: 84995555411     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofw098     Document Type: Article

References (37)

1. Montague CT, O'Rahilly S. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 2000; 49:883-8.
2. Riches FM, Watts GF, Hua J, et al. Reduction in visceral adipose tissue is associated with improvement in apolipoprotein B-100 metabolism in obese men. J Clin Endocrinol Metab 1999; 84:2854-61.
3. Gabriely I, Barzilai N. Surgical removal of visceral adipose tissue: effects on insulin action. Curr Diab Rep 2003; 3:201-6.
4. Phillips GB, Jing T, Heymsfield SB. Relationships in men of sex hormones, insulin, adiposity, and risk factors for myocardial infarction. Metabolism 2003; 52:784-90.
5. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999; 13:2493-505.
6. Bacchetti P, Gripshover B, Grunfeld C, et al. Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005; 40:121-31.
7. Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in women with HIV infection. J Acquir Immune Defic Syndr 2006; 42:562-71.
8. Hadigan C, Meigs JB, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130-9.
9. Grunfeld C, Rimland D, Gibert CL, et al. Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr 2007; 46:283-90.
10. Guaraldi G, Stentarelli C, Zona S, et al. Lipodystrophy and anti-retroviral therapy as predictors of sub-clinical atherosclerosis in human immunodeficiency virus infected subjects. Atherosclerosis 2010; 208:222-7.
11. Orlando G, Guaraldi G, Zona S, et al. Ectopic fat is linked to prior cardiovascular events in men with HIV. J Acquir Immune Defic Syndr 2012; 59:494-7.
12. Karmon SL, Moore RD, Dobs AS, et al. Body shape and composition in HIVinfected women: an urban cohort. HIV Med 2005; 6:245-52.
13. Caron M, Auclair M, Lagathu C, et al. The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 2004; 18:2127-36.
14. Addy CL, Gavrila A, Tsiodras S, et al. Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003; 88:627-36.
15. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13:1659-67.
16. Noor MA, Lo JC, Mulligan K, et al. Metabolic effects of indinavir in healthy HIVseronegative men. AIDS 2001; 15:F11-8.
17. Dube MP, Parker RA, Tebas P, et al. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005; 19:1807-18.
18. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-8.
19. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23:35-43.
20. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 1999; 100:700-5.
21. El-Sadr WM, Mullin CM, Carr A, et al. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med 2005; 6:114-21.
22. Grunfeld C, Pang M, DoerrlerW, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74:1045-52.
23. Gallego-Escuredo JM, Villarroya J, Domingo P, et al. Differentially altered molecular signature of visceral adipose tissue in HIV-1-associated lipodystrophy. J Acquir Immune Defic Syndr 2013; 64:142-8.
24. Post WS, Budoff M, Kingsley L, et al. Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med 2014; 160:458-67.
25. Zanni MV, Abbara S, Lo J, et al. Increased coronary atherosclerotic plaque vulnerability by coronary computed tomography angiography in HIV-infected men. AIDS 2013; 27:1263-72.
26. Kaslow RA, Ostrow DG, Detels R, et al. The Multicenter AIDS Cohort Study: rationale, organization, and selected characteristics of the participants. Am J Epidemiol 1987; 126:310-8.
27. Hacioglu Y, Gupta M, Choi TY, et al. Use of cardiac CT angiography imaging in an epidemiology study-the Methodology of the Multicenter AIDS Cohort Study cardiovascular disease substudy. Anadolu Kardiyol Derg 2013; 13:207-14.
28. Potretzke AM, Schmitz KH, Jensen MD. Preventing overestimation of pixels in computed tomography assessment of visceral fat. Obes Res 2004; 12:1698-701.
29. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130:461-70.
30. Schafer JL. Analysis of IncompleteMultivariateData. London: Chapman & Hall; 1997.
31. Scherzer R, Heymsfield SB, Lee D, et al. Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS 2011; 25:1405-14.
32. Masia M, Padilla S, Garcia N, et al. Endothelial function is impaired in HIVinfected patients with lipodystrophy. Antivir Ther 2010; 15:101-10.
33. Lake JE, Wohl D, Scherzer R, et al. Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study. AIDS Care 2011; 23:929-38.
34. Grinspoon S. Insulin resistance in the HIV-lipodystrophy syndrome. Trends Endocrinol Metab 2001; 12:413-9.
35. Ahmadi N, Nabavi V, Yang E, et al. Increased epicardial, pericardial, and subcutaneous adipose tissue is associated with the presence and severity of coronary artery calcium. Acad Radiol 2010; 17:1518-24.
36. Rodino-Janeiro BK, Salgado-Somoza A, Teijeira-Fernandez E, et al. Receptor for advanced glycation end-products expression in subcutaneous adipose tissue is related to coronary artery disease. Eur J Endocrinol 2011; 164:529-37.
37. Thompson-Paul AM, Lichtenstein KA, Armon C, et al. Cardiovascular Disease Risk Prediction in the HIV Outpatient Study (HOPS). In: Conference on Retroviruses and Opportunistic Infections. Seattle, Washington. 2015. (Abstract Number: 747).